Literature DB >> 20661154

Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis.

Froukje J Verdam1, Sander S Rensen, Ann Driessen, Jan Willem Greve, Willem A Buurman.   

Abstract

BACKGROUND: Endotoxin is hypothesized to play an important role in the activation of inflammatory pathways associated with nonalcoholic steatohepatitis (NASH). However, demonstration of hepatic endotoxin exposure is challenging due to the inaccessibility of the portal circulation. Furthermore, reliable measurement of the relatively low endotoxin levels in plasma of patients with liver disease and subsequent interpretation remain difficult. GOALS: In this study, we used the EndoCab assay that measures endogenous antibodies to the core region of endotoxin to estimate hepatic endotoxin exposure over time. STUDY: IgG levels against endotoxin were measured in peripheral plasma obtained from 21 severely obese patients with NASH and 9 severely obese patients with healthy livers.
RESULTS: Plasma IgG levels against endotoxin were significantly elevated in patients with NASH compared with patients with healthy livers (48±63 GMU/mL vs. 10±13 GMU/mL). Moreover, these IgG levels progressively increased with NASH grade (grade 1 29±37; grade 2 58±51; grade 3 84±132 GMU/mL, P<0.05). There was no relation between plasma IgG levels and NASH stage.
CONCLUSIONS: Plasma IgG levels against endotoxin were found to be increased in biopsy-proven human NASH and increased with aggravated inflammation in NASH, suggesting a relationship between chronic endotoxin exposure and the severity of human NASH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20661154     DOI: 10.1097/MCG.0b013e3181e12c24

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  34 in total

Review 1.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 2.  Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics.

Authors:  Julio Plaza-Diaz; Carolina Gomez-Llorente; Luis Fontana; Angel Gil
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 3.  Gut Microbiota of Nonalcoholic Fatty Liver Disease.

Authors:  Reham M Abdou; Lixin Zhu; Robert D Baker; Susan S Baker
Journal:  Dig Dis Sci       Date:  2016-02-22       Impact factor: 3.199

Review 4.  Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis.

Authors:  Jan Petrasek; Timea Csak; Michal Ganz; Gyongyi Szabo
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

5.  Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells.

Authors:  T Adar; A Ben Ya'acov; G Lalazar; Y Lichtenstein; D Nahman; M Mizrahi; V Wong; B Muller; G Rawlin; Y Ilan
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

6.  Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle.

Authors:  Julia Wattacheril; Kristie L Rose; Salisha Hill; Christian Lanciault; Clark R Murray; Kay Washington; Brandon Williams; Wayne English; Matthew Spann; Ronald Clements; Naji Abumrad; Charles Robb Flynn
Journal:  Hepatol Res       Date:  2017-04-19       Impact factor: 4.288

Review 7.  Obesity, fatty liver disease and intestinal microbiota.

Authors:  Nur Arslan
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 8.  Gut microbiome and metabolic diseases.

Authors:  Shinji Fukuda; Hiroshi Ohno
Journal:  Semin Immunopathol       Date:  2013-11-06       Impact factor: 9.623

Review 9.  The Role of the Microbiome in Liver Cancer.

Authors:  Mar Moreno-Gonzalez; Naiara Beraza
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

10.  Is melatonin associated with pro-inflammatory cytokine activity and liver fibrosis in non-alcoholic fatty liver disease (NAFLD) patients?

Authors:  Masoudreza Sohrabi; Ali Gholami; Bahareh Amirkalali; Mahsa Taherizadeh; Mahsa Kolahdoz; Fahimeh SafarnezhadTameshkel; Sheida Aghili; Marzieh Hajibaba; Farhad Zamani; Mohsen Nasiri Toosi; Hossein Keyvani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.